Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Novel Agents for Treatment of SARS-CoV-2 Infection Among High-Risk Outpatient Adults
NCT04354428Phase 3Terminated
- Sponsor
- University of Washington
- Start
- Apr 2020
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of hydroxychloroquine, azithromycin and lopinavir + ritonavir in coronavirus disease 2019 (COVID-19) (5 arms), sponsored by University of Washington. Primary endpoints: Number of Persons With Lower Respiratory Tract Infection at 28 days, Number of Participants With Hospitalization or Mortality at 28 days and 2 more. Started Apr 2020; status: terminated.
02
Drugs
hydroxychloroquineazithromycinlopinavir + ritonavir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04354428.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04354428.